Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

Concordia University

$34,913.00

The engineering of T-cells using microfluidics for cellular therapies

FY 2020-21

Summary
Preliminary clinical trials harnessing the immune system of cancer patients to combat disease have shown to have impressive efficacy. Immune cells isolated from a patient are genetically altered to allow for improved detection of cancerous cells and subsequently re-introduced into the patient. Yet despite its promise, rapid and cost effective manufacturing of this therapy remains a barrier to widespread adoption. The goal of this project is to develop lab-on-chip platforms to rapidly engineer and to manufacture immune cells that can be potentially used for cellular therapies. Specifically, the manufacturing process of immune cells will involve three steps - engineering, enrichment, and analysis. The overall microfluidic system for manufacturing is compact and portable and therefore can be brought to hospitals, clinics, or research laboratories where it will help streamline the process of engineering immune cells. To achieve this objective, the Shih lab (Concordia) is closely collaborating with Dr. McComb (University of Ottawa) along with the industrial partner DropGenie. DropGenie is a Montreal-based company accelerating the promise of genetic engineering. They would like to develop a lab-on-a-chip approach in which several laboratory operations have been integrated onto a single handheld device, thus allowing for automated liquid handling and optimization of experimental conditions specific to the genetic engineering of immune cells. Streamlining the process will reduce costs and improve accessibility of the therapy for cancer patients while automation will improve standardization and reproducibility of engineering immune cells for cellular therapies in Canada.
Program
Collaborative Research and Development Grants
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
539270-2019
Name nom
Shih, Steve
Department département
Electrical and Computer Engineering
Organization id
70
Institution établissement
Concordia University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2019
Award amount
34913
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Installment
inst:2 - 2
Partie
1
Nb partie
2
Application title
The engineering of T-cells using microfluidics for cellular therapies
Keyword
NSERC
Application summary
Preliminary clinical trials harnessing the immune system of cancer patients to combat disease have shown to have impressive efficacy. Immune cells isolated from a patient are genetically altered to allow for improved detection of cancerous cells and subsequently re-introduced into the patient. Yet despite its promise, rapid and cost effective manufacturing of this therapy remains a barrier to widespread adoption. The goal of this project is to develop lab-on-chip platforms to rapidly engineer and to manufacture immune cells that can be potentially used for cellular therapies. Specifically, the manufacturing process of immune cells will involve three steps - engineering, enrichment, and analysis. The overall microfluidic system for manufacturing is compact and portable and therefore can be brought to hospitals, clinics, or research laboratories where it will help streamline the process of engineering immune cells. To achieve this objective, the Shih lab (Concordia) is closely collaborating with Dr. McComb (University of Ottawa) along with the industrial partner DropGenie. DropGenie is a Montreal-based company accelerating the promise of genetic engineering. They would like to develop a lab-on-a-chip approach in which several laboratory operations have been integrated onto a single handheld device, thus allowing for automated liquid handling and optimization of experimental conditions specific to the genetic engineering of immune cells. Streamlining the process will reduce costs and improve accessibility of the therapy for cancer patients while automation will improve standardization and reproducibility of engineering immune cells for cellular therapies in Canada.
Concordia University - $34,913 Grant (2020-21) | Canada Spends